Allowing Novo-Catalent deal to close would be ‘wrong decision’ by antitrust authorities, Roche CEO says

An­titrust reg­u­la­tors shouldn’t clear No­vo Hold­ings’ planned ac­qui­si­tion of Catal­ent, Roche CEO Thomas Schi­neck­er said Wednes­day, adding to the pres­sure that in­dus­try com­peti­tors ap­pear to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.